Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.

Also called NCT05677334

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 210 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05677334
Other papers using this trial's data
  • A Multicentre, Randomised, Controlled, Open-Label Study of Continuous Subcutaneous Insulin Infusion Plus Henagliflozin for Treating Type 2 Diabetes Mellitus Patients With Severe Hyperglycaemia Diabetes, obesity & metabolism, 2026-06 DOI, PubMed 41853855

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05677334. Randomized; no masking; primary purpose treatment. Start 2023-03-01 (actual); primary completion 2024-10-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM
Condition
Type2diabetes
Intervention (Drug)
Henagliflozin
Intervention (Device)
Continuous Subcutaneous Insulin Infusion
Lead sponsor
First Affiliated Hospital of Guangxi Medical University (class: other)

Record details

Record id
cardio:ct-nct05677334
Content hash
bcb3d2923eae5aa07ee9f4041651d39d1d818fe3f7553ba76f5f53c86cc449a9